Regulus Therapeutics Surges 11% Amid Deutsche Bank Report
November 24, 2014 at 15:20 PM EST
Deutsche Bank initiated coverage on Regulus Therapeutics Inc (NASDAQ: RGLS) in a report issued Monday with a Buy rating and $30 price ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |